UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. )*
SHAMAN PHARMACEUTICALS, INC.
(Name of Issuer)
Common Stock, $.001 par value
(Title of Class of Securities)
819319401
(CUSIP Number)
November 30, 1999
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
</Page>
SCHEDULE 13G
CUSIP NO. 819319401 PAGE 2 OF 11 PAGES
- - ------------------------------------------------------------------------- -
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Advantage Fund II Ltd.
- - ------------------------------------------------------------------------- -
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A)[ ]
(B)[ ]
- - ------------------------------------------------------------------------- -
3 SEC USE ONLY
- - ------------------------------------------------------------------------- -
4 CITIZENSHIP OR PLACE OF ORGANIZATION
British Virgin Islands
- - ------------------------------------------------------------------------- -
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY ---------------------------------------------------- -
EACH 6 SHARED VOTING POWER
REPORTING
PERSON 6,678,635
WITH: ---------------------------------------------------- -
7 SOLE DISPOSITIVE POWER
-0-
---------------------------------------------------- -
8 SHARED DISPOSITIVE POWER
6,678,635
- - ------------------------------------------------------------------------- -
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,678,635
- - ------------------------------------------------------------------------- -
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
- - ------------------------------------------------------------------------- -
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
10.3%
- - ------------------------------------------------------------------------- -
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- - ------------------------------------------------------------------------- -
</Page>
SCHEDULE 13G
CUSIP NO. 819319401 PAGE 3 OF 11 PAGES
- - ------------------------------------------------------------------------- -
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Genesee Fund Limited - Portfolio B
- - ------------------------------------------------------------------------- -
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A)[ ]
(B)[ ]
- - ------------------------------------------------------------------------- -
3 SEC USE ONLY
- - ------------------------------------------------------------------------- -
4 CITIZENSHIP OR PLACE OF ORGANIZATION
British Virgin Islands
- - ------------------------------------------------------------------------- -
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY ---------------------------------------------------- -
EACH 6 SHARED VOTING POWER
REPORTING
PERSON 415,050
WITH: ---------------------------------------------------- -
7 SOLE DISPOSITIVE POWER
-0-
---------------------------------------------------- -
8 SHARED DISPOSITIVE POWER
415,050
- - ------------------------------------------------------------------------- -
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
415,050
- - ------------------------------------------------------------------------- -
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
- - ------------------------------------------------------------------------- -
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.6%
- - ------------------------------------------------------------------------- -
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- - ------------------------------------------------------------------------- -
</Page>
SCHEDULE 13G
CUSIP NO. 819319401 PAGE 4 OF 11 PAGES
- - ------------------------------------------------------------------------- -
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Genesee International, Inc.
- - ------------------------------------------------------------------------- -
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A)[ ]
(B)[ ]
- - ------------------------------------------------------------------------- -
3 SEC USE ONLY
- - ------------------------------------------------------------------------- -
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- - ------------------------------------------------------------------------- -
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY ---------------------------------------------------- -
EACH 6 SHARED VOTING POWER
REPORTING
PERSON 7,093,685
WITH: ---------------------------------------------------- -
7 SOLE DISPOSITIVE POWER
-0-
---------------------------------------------------- -
8 SHARED DISPOSITIVE POWER
7,093,685
- - ------------------------------------------------------------------------- -
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,093,685
- - ------------------------------------------------------------------------- -
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
- - ------------------------------------------------------------------------- -
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
10.9%
- - ------------------------------------------------------------------------- -
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- - ------------------------------------------------------------------------- -
</Page>
SCHEDULE 13G
CUSIP NO. 819319401 PAGE 5 OF 11 PAGES
- - ------------------------------------------------------------------------- -
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Donald R. Morken
- - ------------------------------------------------------------------------- -
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A)[ ]
(B)[ ]
- - ------------------------------------------------------------------------- -
3 SEC USE ONLY
- - ------------------------------------------------------------------------- -
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- - ------------------------------------------------------------------------- -
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY ---------------------------------------------------- -
EACH 6 SHARED VOTING POWER
REPORTING
PERSON 7,093,685
WITH: ---------------------------------------------------- -
7 SOLE DISPOSITIVE POWER
-0-
---------------------------------------------------- -
8 SHARED DISPOSITIVE POWER
7,093,685
- - ------------------------------------------------------------------------- -
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,093,685
- - ------------------------------------------------------------------------- -
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
- - ------------------------------------------------------------------------- -
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
10.9%
- - ------------------------------------------------------------------------- -
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN
- - ------------------------------------------------------------------------- -
</Page>
SCHEDULE 13G
CUSIP NO. 819319401 PAGE 6 OF 11 PAGES
Item 1. Name and Address of Issuer:
Shaman Pharmaceuticals, Inc.
213 East Grand Avenue
South San Francisco, California 94080-4812
Item 2. (a) Names of Persons Filing:
Advantage Fund II Ltd. ("Advantage")
Genesee Fund - Limited Portfolio B ("Genesee Fund")
Genesee International, Inc. ("Genesee
International")
Donald R. Morken ("Mr. Morken")
(b) Address of Principal Business Office:
Advantage:
c/o CITCO
Kaya Flamboyan 9
Curacao, Netherlands Antilles
Genesee Fund:
c/o CITCO
Kaya Flamboyan 9
Curacao, Netherlands Antilles
Genesee International:
CITCO Building
Wickhams Cay
P.O. Box 662
Road Town
Tortola, British Virgin Islands
Mr. Morken:
10500 N.E. 8th Street
Suite 1920
Bellevue, Washington 98004-4332
(c) Place of Organization or Citizenship:
Advantage: British Virgin Islands
Genesee Fund: British Virgin Islands
Genesee International: Delaware
Mr. Morken: citizen of the United States
(d) Title of Class of Securities:
Common Stock, $.001 par value
</Page>
SCHEDULE 13G
CUSIP NO. 819319401 PAGE 7 OF 11 PAGES
(e) CUSIP Number:
819319401
Item 3. This statement is filed pursuant to Rule 13d-1(c) by
Advantage, Genesee Fund, Genesee International and Mr.
Morken.
Item 4. Ownership:
(a) Amount Beneficially Owned by Advantage, Genesee Fund,
Genesee International and Mr. Morken:
Advantage: 6,678,635
Genesee Fund: 415,050
Genesee International: 7,093,685
Mr. Morken: 7,093,685
(b) Percent of Class:
Advantage: 10.3%
Genesee Fund: 0.6%
Genesee International: 10.9%
Mr. Morken: 10.9%
The Issuer advised Genesee International that
64,245,959 shares of Common Stock were outstanding as
of November 30, 1999. This amount was used to
determine the percentages of outstanding shares of
Common Stock reported in this statement.
(c) Number of Shares as to which the Person has:
(i) sole power to vote or to direct
the vote
Advantage: -0-
Genesee Fund: -0-
Genesee International: -0-
Mr. Morken: -0-
(ii) shared power to vote or to
direct the vote
Advantage: 6,678,635
Genesee Fund: 415,050
Genesee International: 7,093,685
Mr. Morken: 7,093,685
</Page>
SCHEDULE 13G
CUSIP NO. 819319401 PAGE 8 OF 11 PAGES
(iii) sole power to dispose or to
direct the disposition of
Advantage: -0-
Genesee Fund: -0-
Genesee International: -0-
Mr. Morken: -0-
(iv) shared power to dispose or to
direct the disposition of
Advantage: 6,678,635
Genesee Fund: 415,050
Genesee International: 7,093,685
Mr. Morken: 7,093,685
The shares of Common Stock reported above in this Item 4 as
beneficially owned by the reporting persons consist of (i)
shares owned directly by Advantage and (ii) shares issuable
to Advantage and Genesee Fund upon the exercise of certain
warrants of the Issuer (the "Warrants") to purchase shares
of Series R Convertible Preferred Stock of the Issuer (the
"Series R Preferred Stock"), which shares are in turn
convertible into shares of Common Stock, in each case as of
the close of business on November 30, 1999. Prior to the
close of business on November 30, 1999, Advantage sold an
aggregate of 4,265,000 shares of Common Stock. If such sale
was not taken into account in determining the number of
shares of Common Stock reported above in this Item 4, the
amount of shares beneficially owned and the percent of class
represented thereby for each of the reporting persons would
be as follows:
No. of Shares Percent of Class
Advantage: 10,943,635 16.9%
Genesee Fund: 415,050 0.6%
Genesee International: 11,358,685 17.5%
Mr. Morken: 11,358,685 17.5%
In accordance with the terms of the Series R Preferred
Stock, if Advantage and Genesee Fund exercise their Warrants
they may be entitled to receive additional shares of Common
Stock when the Series R Preferred Stock first becomes
convertible, and is automatically converted, into shares of
Common Stock on February 1, 2000.
Item 5. Ownership of Five Percent or Less of a Class:
Not applicable
</Page>
SCHEDULE 13G
CUSIP NO. 819319401 PAGE 9 OF 11 PAGES
Item 6. Ownership of More Than Five Percent on Behalf of Another
Person:
Not applicable
Item 7. Identification and Classification of the Subsidiary which
Acquired the Security Being Reported on by the Parent
Holding Company:
Not applicable
Item 8. Identification and Classification of Members of the Group:
Not applicable
Item 9. Notice of Dissolution of Group:
Not applicable
Item 10. Certification:
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the
effect of changing or influencing the control of the issuer
of the securities and were not acquired and are not held in
connection with or as a participant in any transaction
having that purpose or effect.
Exhibits:
1. Joint Filing Agreement, dated as of December 10, 1999, among
Advantage, Genesee Fund, Genesee International and Mr. Morken.
</Page>
SCHEDULE 13G
CUSIP NO. 819319401 PAGE 10 OF 11 PAGES
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is
true, complete and correct.
ADVANTAGE FUND II LTD.
By: Genesee International, Inc.,
as General Manager
By: /s/ Donald R. Morken
---------------------------
Name: Donald R. Morken
Title: President
Dated: December 10, 1999
GENESEE FUND LIMITED - PORTFOLIO B
By: Genesee International, Inc.,
as General Manager
By: /s/ Donald R. Morken
---------------------------
Name: Donald R. Morken
Title: President
Dated: December 10, 1999
GENESEE INTERNATIONAL, INC.
By: /s/ Donald R. Morken
---------------------------
Name: Donald R. Morken
Title: President
Dated: December 10, 1999
/s/ Donald R. Morken
---------------------------
Donald R. Morken
Dated: December 10, 1999
</Page>
SCHEDULE 13G
CUSIP NO. 819319401 PAGE 11 OF 11 PAGES
Exhibit 1
---------
JOINT FILING AGREEMENT
----------------------
This will confirm the agreement by and among the undersigned that
the Schedule 13G filed with the Securities and Exchange Commission on or about
the date hereof with respect to the beneficial ownership of the undersigned of
shares of Common Stock, $.001 par value, of Shaman Pharmaceuticals, Inc., a
Delaware corporation, is being filed, and all amendments thereto will be
filed, on behalf of each of the persons and entities named below in accordance
with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
This Agreement may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one
and the same instrument.
Dated: as of December 10, 1999
ADVANTAGE FUND II LTD.
By: Genesee International, Inc.,
as General Manager
By: /s/ Donald R. Morken
---------------------------
Name: Donald R. Morken
Title: President
GENESEE FUND LIMITED - PORTFOLIO B
By: Genesee International, Inc.,
as General Manager
By: /s/ Donald R. Morken
---------------------------
Name: Donald R. Morken
Title: President
GENESEE INTERNATIONAL, INC.
By: /s/ Donald R. Morken
---------------------------
Name: Donald R. Morken
Title: President
/s/ Donald R. Morken
---------------------------
Donald R. Morken
